Profile data is unavailable for this security.
About the company
Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.
- Revenue in AUD (TTM)9.76m
- Net income in AUD-8.17m
- Incorporated1997
- Employees50.00
- LocationStarpharma Holdings Ltd4-6 Southampton Crescent, AbbotsfordMELBOURNE 3067AustraliaAUS
- Phone+61 38532-2700
- Fax+61 39510-5955
- Websitehttps://www.starpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oncosil Medical Ltd | 583.20k | -11.91m | 31.32m | 2.00 | -- | 4.92 | -- | 53.70 | -0.0054 | -0.0054 | 0.0003 | 0.0014 | 0.0641 | -- | 3.12 | -- | -130.97 | -67.66 | -162.31 | -77.45 | -158.87 | -- | -2,042.81 | -768.23 | -- | -- | 0.0147 | -- | 35.54 | -31.37 | -5.03 | -- | 67.76 | -- |
| Little Green Pharma Ltd | 25.63m | -8.15m | 39.37m | -- | -- | 0.505 | -- | 1.54 | -0.0272 | -0.0272 | 0.0856 | 0.2574 | 0.2772 | 1.05 | 12.29 | -- | -8.82 | -- | -9.74 | -- | 53.18 | -- | -31.81 | -- | 1.39 | -18.90 | 0.0624 | -- | 29.07 | -- | 4.72 | -- | -- | -- |
| Next Science Ltd | 35.84m | -20.76m | 41.63m | -- | -- | 3.82 | -- | 1.16 | -0.0773 | -0.0773 | 0.1315 | 0.0373 | 1.97 | 5.34 | 8.04 | -- | -113.88 | -74.40 | -168.92 | -90.31 | 78.83 | 76.98 | -57.93 | -128.26 | 1.96 | -- | 0.1045 | -- | 89.36 | 50.80 | -28.29 | -- | -2.28 | -- |
| Medical Developments International Ltd | 33.15m | -40.99m | 47.88m | 68.00 | -- | 0.8234 | -- | 1.44 | -0.4627 | -0.4627 | 0.3741 | 0.5162 | 0.4131 | 1.02 | 4.14 | -- | -51.09 | -15.81 | -60.56 | -17.79 | 73.50 | 70.98 | -123.66 | -52.49 | 1.82 | -- | 0.0476 | -- | 2.51 | 9.22 | -630.83 | -- | -20.32 | -- |
| Starpharma Holdings Ltd | 9.76m | -8.17m | 48.08m | 50.00 | -- | 1.69 | -- | 4.93 | -0.0198 | -0.0198 | 0.0237 | 0.0682 | 0.2195 | 0.244 | 1.20 | -- | -18.37 | -27.20 | -24.10 | -33.05 | 93.52 | 77.48 | -83.69 | -269.74 | 4.58 | -- | 0.1115 | -- | 131.84 | 29.10 | 47.79 | -- | -22.29 | -- |
| Inoviq Ltd | 791.70k | -6.55m | 49.63m | 85.00 | -- | 2.35 | -- | 62.69 | -0.0709 | -0.0709 | 0.0086 | 0.1894 | 0.0366 | 4.54 | 0.6418 | -- | -30.33 | -44.62 | -32.64 | -47.55 | 89.77 | -- | -827.88 | -1,928.52 | 7.06 | -- | 0.0198 | -- | 5.29 | 146.33 | 26.92 | -- | -- | -- |
| Vitura Health Ltd | 123.87m | 3.51m | 56.44m | 119.00 | 15.88 | 1.46 | 11.55 | 0.4556 | 0.0062 | 0.0062 | 0.2165 | 0.0674 | 2.10 | 15.04 | 10.74 | 1,040,932.00 | 5.50 | 13.50 | 7.70 | 18.51 | 27.63 | 32.41 | 2.62 | 6.19 | 1.11 | 30.48 | 0.2228 | -- | 5.56 | -- | -74.57 | -- | 155.80 | -- |
| Radiopharm Theranostics Ltd | 299.23k | -47.95m | 56.50m | -- | -- | 0.4256 | -- | 188.81 | -0.1261 | -0.1261 | 0.0008 | 0.0611 | 0.0041 | -- | 0.1097 | -- | -65.24 | -- | -82.85 | -- | -- | -- | -16,024.17 | -- | -- | -3.91 | 0.00 | -- | 2.35 | -- | -38.54 | -- | -- | -- |
| Syntara Ltd | 5.43m | -13.67m | 57.67m | 107.00 | -- | 10.72 | -- | 10.62 | -0.0157 | -0.016 | 0.0057 | 0.0039 | 0.3155 | -- | 0.7918 | -- | -79.44 | -30.68 | -130.63 | -40.26 | -- | -- | -251.77 | -74.66 | -- | -484.90 | 0.0474 | -- | -7.92 | -15.43 | -1.77 | -- | -62.79 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Allianz Global Investors Asia Pacific Ltd.as of 11 Aug 2023 | 48.48m | 11.60% |
| ICM Investment Management Ltd.as of 11 Aug 2023 | 21.36m | 5.11% |
| Allan Gray Australia Pty Ltd.as of 05 Sep 2024 | 20.84m | 4.98% |
| FIL Investment Advisors (UK) Ltd.as of 27 Sep 2023 | 20.29m | 4.85% |
| M&G Investment Management Ltd.as of 19 Oct 2023 | 18.16m | 4.34% |
| FIL Investment Management (Hong Kong) Ltd.as of 30 Sep 2024 | 14.02m | 3.35% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 2.50m | 0.60% |
| Russell Investment Management Ltd.as of 28 Jun 2024 | 1.32m | 0.32% |
| Mirrabooka Investments Ltd. (Investment Management)as of 30 Jun 2024 | 0.00 | 0.00% |
